Mersana Therapeutics' Series C Round

Mersana Therapeutics raised a round of funding on June 16, 2016.

Mersana Therapeutics (NASDAQ: MRSN) is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patient…

Articles about Mersana Therapeutics' Series C Round: